Back to search
Histiocytosis, Langerhans-Cell
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Histiocytosis, Langerhans-Cell trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Histiocytosis, Langerhans-Cell trials you may qualify forThis phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that…
This open-label study aims to gather long-term safety, tolerability, PK, biomarker, and clinical efficacy data relating to daily administration of Nizubaglustat…
An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late…
An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late…
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patient…
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
The purpose of this study is to try to understand how histopcytosis can cause symptoms or problems in the brain. The tests being done in the study will look at…
The purpose of this study is to use agnostic genomic evaluation using whole exome sequencing (WES) of a variety of rare hematologic diseases grouped under rare…
Immunotherapy is changing the landscape of cancer therapy. Particularly unique to immunotherapy is the toxicity profile, which differs from chemotherapy-based s…